Connection

Jordan Elm to Middle Aged

Back to Details
This is a "connection" page, showing publications Jordan Elm has written about Middle Aged.
Jordan Elm
Connection Strength
0.503
Middle Aged
  1. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21.
    View in: PubMed
    Score: 0.030
  2. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.021
  3. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007 Apr 30; 22(6):822-7.
    View in: PubMed
    Score: 0.021
  4. Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. Neurology. 2021 08 17; 97(7):e720-e727.
    View in: PubMed
    Score: 0.014
  5. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clin Transl Sci. 2021 07; 14(4):1444-1451.
    View in: PubMed
    Score: 0.014
  6. Early Neurologic Recovery, Practice Pattern Variation, and the Risk of Endotracheal Intubation Following Established Status Epilepticus. Neurology. 2021 05 11; 96(19):e2372-e2386.
    View in: PubMed
    Score: 0.013
  7. Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial. J Am Heart Assoc. 2021 03 16; 10(6):e019362.
    View in: PubMed
    Score: 0.013
  8. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020 07; 51(7):2058-2065.
    View in: PubMed
    Score: 0.013
  9. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 04 11; 395(10231):1217-1224.
    View in: PubMed
    Score: 0.013
  10. Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke. 2020 03; 51(3):792-799.
    View in: PubMed
    Score: 0.012
  11. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 11 28; 381(22):2103-2113.
    View in: PubMed
    Score: 0.012
  12. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
    View in: PubMed
    Score: 0.012
  13. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. JAMA Neurol. 2019 07 01; 76(7):774-782.
    View in: PubMed
    Score: 0.012
  14. Factors Influencing Oral Intake Improvement and Feeding Tube Dependency in Patients with Poststroke Dysphagia. J Stroke Cerebrovasc Dis. 2019 Jun; 28(6):1421-1430.
    View in: PubMed
    Score: 0.012
  15. Mapping acute lesion locations to physiological swallow impairments after stroke. Neuroimage Clin. 2019; 22:101685.
    View in: PubMed
    Score: 0.012
  16. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease. BMC Med Inform Decis Mak. 2018 12 20; 18(1):138.
    View in: PubMed
    Score: 0.012
  17. Transcranial Direct Current Stimulation vs Sham Stimulation to Treat Aphasia After Stroke: A Randomized Clinical Trial. JAMA Neurol. 2018 12 01; 75(12):1470-1476.
    View in: PubMed
    Score: 0.011
  18. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial. Neurology. 2018 12 04; 91(23):e2163-e2169.
    View in: PubMed
    Score: 0.011
  19. Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage. Stroke. 2018 11; 49(11):2652-2658.
    View in: PubMed
    Score: 0.011
  20. BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul. 2018 Nov - Dec; 11(6):1276-1281.
    View in: PubMed
    Score: 0.011
  21. Long-Term Outcomes in Patients Aged =70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis. Stroke. 2018 06; 49(6):1457-1463.
    View in: PubMed
    Score: 0.011
  22. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19; 379(3):215-225.
    View in: PubMed
    Score: 0.011
  23. Differences in swallow physiology in patients with left and right hemispheric strokes. Physiol Behav. 2018 10 01; 194:144-152.
    View in: PubMed
    Score: 0.011
  24. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143.
    View in: PubMed
    Score: 0.010
  25. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
    View in: PubMed
    Score: 0.010
  26. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct; 15(11):1160-9.
    View in: PubMed
    Score: 0.010
  27. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 05; 31(5):709-14.
    View in: PubMed
    Score: 0.010
  28. Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design. Neurocrit Care. 2016 Feb; 24(1):132-9.
    View in: PubMed
    Score: 0.009
  29. Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One. 2015; 10(7):e0133002.
    View in: PubMed
    Score: 0.009
  30. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
    View in: PubMed
    Score: 0.009
  31. Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale. J Parkinsons Dis. 2015; 5(1):67-73.
    View in: PubMed
    Score: 0.009
  32. Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis. 2015; 5(4):731-6.
    View in: PubMed
    Score: 0.009
  33. Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis. 2015; 5(4):773-82.
    View in: PubMed
    Score: 0.009
  34. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014 Aug; 21(1):43-51.
    View in: PubMed
    Score: 0.009
  35. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014 Apr; 20(2):193-201.
    View in: PubMed
    Score: 0.008
  36. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord. 2014 Feb; 29(2):263-5.
    View in: PubMed
    Score: 0.008
  37. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014 Jan; 45(1):281-3.
    View in: PubMed
    Score: 0.008
  38. The established status epilepticus trial 2013. Epilepsia. 2013 Sep; 54 Suppl 6:89-92.
    View in: PubMed
    Score: 0.008
  39. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S130-7.
    View in: PubMed
    Score: 0.008
  40. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83.
    View in: PubMed
    Score: 0.008
  41. A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. Clin Trials. 2012 Apr; 9(2):188-97.
    View in: PubMed
    Score: 0.007
  42. Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke. J Stroke Cerebrovasc Dis. 2013 Aug; 22(6):742-9.
    View in: PubMed
    Score: 0.007
  43. How common is brain atrophy in patients with medial temporal lobe epilepsy? Epilepsia. 2010 Sep; 51(9):1774-9.
    View in: PubMed
    Score: 0.006
  44. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism Relat Disord. 2010 Sep; 16(8):507-12.
    View in: PubMed
    Score: 0.006
  45. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.006
  46. Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord. 2010 Jan; 16(1):60-3.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.